Should all adjuvant breast cancer patients receive a bisphosphonate?

Research output: Contribution to journalArticlepeer-review


This commentary discusses the report by Trevor Powles and colleagues on their double-blind, placebo-controlled randomised trial of 2 years' adjuvant oral clodronate. Although the reported survival benefit in the clodronate-treated group confirms the results of one prior study as well as the generally held view that bisphosphonates could be advantageous, the reviewer does not feel that the data support the universal use of this additional adjuvant therapy.
Original languageEnglish
Pages (from-to)296-9
Number of pages4
JournalBreast Cancer Research
Issue number6
Publication statusPublished - 2003


  • Antimetabolites
  • Breast Neoplasms
  • Clodronic Acid
  • Female
  • Follow-Up Studies
  • Humans
  • Treatment Outcome


Dive into the research topics of 'Should all adjuvant breast cancer patients receive a bisphosphonate?'. Together they form a unique fingerprint.

Cite this